[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201000050A1 - Замещенные бициклолактамные соединения - Google Patents

Замещенные бициклолактамные соединения

Info

Publication number
EA201000050A1
EA201000050A1 EA201000050A EA201000050A EA201000050A1 EA 201000050 A1 EA201000050 A1 EA 201000050A1 EA 201000050 A EA201000050 A EA 201000050A EA 201000050 A EA201000050 A EA 201000050A EA 201000050 A1 EA201000050 A1 EA 201000050A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
bicycloplastic
substituted
obesity
diabetes
Prior art date
Application number
EA201000050A
Other languages
English (en)
Inventor
Роберт Ли Доу
Майкл Джон Манкхоф
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA201000050A1 publication Critical patent/EA201000050A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Согласно настоящему изобретению предложены соединения формулы (1) и их фармацевтически приемлемая соль, где R', R, R, R, R, R, R, R, Q, A, Z и Rявляются такими, как они приведены в данном описании; их композиции и их применения для лечения диабета и ожирения.
EA201000050A 2007-08-02 2008-07-22 Замещенные бициклолактамные соединения EA201000050A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95350707P 2007-08-02 2007-08-02
PCT/IB2008/001963 WO2009016462A2 (en) 2007-08-02 2008-07-22 Substituted bicyclolactam compounds

Publications (1)

Publication Number Publication Date
EA201000050A1 true EA201000050A1 (ru) 2010-08-30

Family

ID=39926534

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000050A EA201000050A1 (ru) 2007-08-02 2008-07-22 Замещенные бициклолактамные соединения

Country Status (34)

Country Link
US (2) US20090036425A1 (ru)
EP (1) EP2185567B1 (ru)
JP (1) JP4629808B2 (ru)
KR (1) KR20100032443A (ru)
CN (1) CN101772504A (ru)
AP (1) AP2010005163A0 (ru)
AR (1) AR067780A1 (ru)
AT (1) ATE502948T1 (ru)
AU (1) AU2008281545B2 (ru)
BR (1) BRPI0815067A2 (ru)
CA (1) CA2695291C (ru)
CL (1) CL2008002227A1 (ru)
CO (1) CO6251365A2 (ru)
CR (1) CR11223A (ru)
CY (1) CY1111628T1 (ru)
DE (1) DE602008005757D1 (ru)
DK (1) DK2185567T3 (ru)
DO (1) DOP2010000046A (ru)
EA (1) EA201000050A1 (ru)
EC (1) ECSP109932A (ru)
ES (1) ES2361716T3 (ru)
HN (1) HN2008001191A (ru)
HR (1) HRP20110335T1 (ru)
MA (1) MA31580B1 (ru)
PA (1) PA8791601A1 (ru)
PE (1) PE20090897A1 (ru)
PL (1) PL2185567T3 (ru)
PT (1) PT2185567E (ru)
SI (1) SI2185567T1 (ru)
TN (1) TN2010000053A1 (ru)
TW (1) TWI356059B (ru)
UA (1) UA94833C2 (ru)
WO (1) WO2009016462A2 (ru)
ZA (1) ZA201000255B (ru)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005315430B2 (en) 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
CN101346387A (zh) 2005-12-22 2009-01-14 阿斯利康(瑞典)有限公司 用作DGAT抑制剂的嘧啶并-[4,5-b]-噁嗪
EP2301923B1 (en) 2006-03-31 2016-06-08 Novartis AG Pyridine derivatives as dgat inhibitors
JP2009538892A (ja) 2006-05-30 2009-11-12 アストラゼネカ アクチボラグ アセチル補酵素ａジアシルグリセロールアシルトランスフェラーゼの阻害薬としての置換５−フェニルアミノ−１，３，４−オキサジアゾール−２−イルカルボニルアミノ−４−フェノキシ−シクロヘキサンカルボン酸
UA98772C2 (ru) 2006-06-23 2012-06-25 Эбботт Леборетриз Производные циклопропиламина как модуляторы н3-гистаминового рецептора
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
TW201038580A (en) * 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010089685A1 (en) * 2009-02-03 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
WO2010089686A1 (en) * 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
DK3366686T3 (da) 2009-03-20 2020-11-23 Metabasis Therapeutics Inc Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
DK2547679T3 (en) 2010-03-19 2016-01-11 Pfizer 2,3 dihydro-1H-inden-1-yl-2,7-diazaspiro [3.6] nonane derivatives and their use as antagonists or inverse agonists of ghrelin receptor
WO2011121350A1 (en) 2010-04-01 2011-10-06 Astrazeneca Ab 4 -amino -7,8- dihydropyrimido [5, 4 - f] [1, 4] oxazepin- 5 ( 6h) - one based dgat1 inhibitors
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2012056372A1 (en) 2010-10-29 2012-05-03 Pfizer Inc. N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
WO2012112364A1 (en) * 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
WO2012122075A1 (en) * 2011-03-08 2012-09-13 Merck Sharp & Dohme Corp. Lactam derivatives as dgat-1 inhibitors
RS54526B1 (en) 2011-04-22 2016-06-30 Pfizer Inc. USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS
MX361350B (es) 2011-05-10 2018-12-04 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal de sodio.
PE20141204A1 (es) 2011-05-20 2014-10-05 Glaxosmithkline Ip No 2 Ltd Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (ru) 2011-07-01 2018-04-28
JP2014520879A (ja) 2011-07-15 2014-08-25 ファイザー・インク Ｇｐｒ１１９調節因子
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013068439A1 (en) * 2011-11-09 2013-05-16 Intervet International B.V. 4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
SG11201401531RA (en) 2011-11-11 2014-07-30 Pfizer 2-thiopyrimidinones
CN104245696A (zh) * 2012-02-07 2014-12-24 凯诺斯医药公司 作为1型二酰基甘油o-酰基转移酶的抑制剂的化合物
MX2014011373A (es) 2012-04-06 2014-10-14 Pfizer Inhibidores de diacilglicerol aciltransferasa 2.
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
MX2014012937A (es) * 2012-04-25 2015-05-11 Korea Res Inst Chem Tech Derivados novedosos de beta-alanina, sales farmaceuticamente aceptables del los mismos y una composicion farmaceutica que comprende los mismos como el ingrediente activo.
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
BR112014031108A2 (pt) 2012-06-20 2017-06-27 Hoffmann La Roche compostos de pirazol substituído como antagonistas de lpar
EP2897964A1 (en) 2012-09-20 2015-07-29 Pfizer Inc. Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
JP6099753B2 (ja) * 2012-10-03 2017-03-22 アドビナス セラピューティクス リミテッド スピロ環化合物、その組成物及びその医薬応用
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
LT2922551T (lt) * 2012-11-23 2019-02-11 Glaxosmithkline Llc Nauji junginiai, kaip diacilglicerolio aciltransferazės inhibitoriai
CA2893256A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
WO2014097038A1 (en) 2012-12-19 2014-06-26 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
CA2897678A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014140241A1 (en) * 2013-03-15 2014-09-18 Intervet International B.V. Pyridine derivatives as dgat-1 inhibitors
CN104418866B (zh) 2013-08-23 2018-10-16 青岛黄海制药有限责任公司 Dgat1抑制剂及其制备方法和用途
JP6348582B2 (ja) 2013-10-09 2018-06-27 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
PL3119757T3 (pl) 2014-03-17 2018-09-28 Pfizer Inc. Inhibitory diacyloglicerolo acylotransferazy 2 do stosowania w leczeniu zaburzeń metabolicznych i związanych
UA121467C2 (uk) 2014-04-04 2020-06-10 Пфайзер Інк. Біциклічні анельовані гетероарильні або арильні сполуки та їх застосування як інгібіторів irak4
EP3129388A1 (en) 2014-04-10 2017-02-15 Pfizer Inc. 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
KR20170132326A (ko) 2015-05-05 2017-12-01 화이자 인코포레이티드 2-티오피리미딘온
WO2016193844A1 (en) 2015-05-29 2016-12-08 Pfizer Inc. Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
HUE051898T2 (hu) 2015-06-17 2021-03-29 Pfizer Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
BR112018002071A2 (pt) 2015-08-13 2018-09-18 Pfizer compostos heteroarílicos ou arílicos fundidos bicíclicos
EP3858825A1 (en) 2015-08-27 2021-08-04 Pfizer Inc. Bicyclic-fused heteroaryl compounds as irak4 modulators
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
EP3353182A1 (en) 2015-09-24 2018-08-01 Pfizer Inc Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
BR112018003489A2 (pt) 2015-09-24 2018-09-25 Pfizer n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
US9809579B2 (en) 2015-12-29 2017-11-07 Pfizer Inc. Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
WO2018011681A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN108164548B (zh) * 2016-12-07 2020-09-08 四川大学 嘧啶并吗啉衍生物及其制备方法和用途
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
CA3110601C (en) 2018-08-31 2023-09-05 Pfizer Inc. Combinations for treatment of nash/nafld and related diseases
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
JP7498199B2 (ja) 2019-06-28 2024-06-11 ファイザー・インク 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
EP4097099B1 (en) 2020-02-07 2024-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
PE20241590A1 (es) 2021-12-01 2024-08-01 Pfizer Derivados del acido 3-fenil-1-benzotiofeno-2-carboxilico como inhibidores de la quinasa deshidrogenasa de alfa cetoacidos de cadena ramificada para el tratamiento de la diabetes, enfermedades renales, nash e insuficiencia cardiaca
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1297559C (zh) * 2002-01-18 2007-01-31 杏林制药株式会社 稠合双环嘧啶衍生物
CA2514473C (en) * 2002-11-22 2008-05-27 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
EP1718309A2 (en) * 2004-01-30 2006-11-08 Japan Tobacco, Inc. Anorectic compounds
JP2006056881A (ja) * 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
CN101346387A (zh) * 2005-12-22 2009-01-14 阿斯利康(瑞典)有限公司 用作DGAT抑制剂的嘧啶并-[4,5-b]-噁嗪

Also Published As

Publication number Publication date
UA94833C2 (en) 2011-06-10
WO2009016462A2 (en) 2009-02-05
EP2185567B1 (en) 2011-03-23
CY1111628T1 (el) 2015-10-07
TN2010000053A1 (fr) 2011-09-26
KR20100032443A (ko) 2010-03-25
EP2185567A2 (en) 2010-05-19
AP2010005163A0 (en) 2010-02-28
DK2185567T3 (da) 2011-05-16
PT2185567E (pt) 2011-05-27
PA8791601A1 (es) 2009-12-16
BRPI0815067A2 (pt) 2015-02-10
WO2009016462A3 (en) 2009-03-26
AU2008281545B2 (en) 2011-12-08
US20090137551A1 (en) 2009-05-28
TWI356059B (en) 2012-01-11
JP2010535190A (ja) 2010-11-18
US20090036425A1 (en) 2009-02-05
ES2361716T3 (es) 2011-06-21
CA2695291A1 (en) 2009-02-05
HRP20110335T1 (hr) 2011-06-30
ATE502948T1 (de) 2011-04-15
DE602008005757D1 (de) 2011-05-05
CN101772504A (zh) 2010-07-07
HN2008001191A (es) 2012-01-17
MA31580B1 (fr) 2010-08-02
CR11223A (es) 2010-02-04
DOP2010000046A (es) 2010-03-31
SI2185567T1 (sl) 2011-06-30
AR067780A1 (es) 2009-10-21
CL2008002227A1 (es) 2009-04-17
JP4629808B2 (ja) 2011-02-09
CA2695291C (en) 2012-04-17
US7718645B2 (en) 2010-05-18
AU2008281545A1 (en) 2009-02-05
PL2185567T3 (pl) 2011-07-29
CO6251365A2 (es) 2011-02-21
TW200916471A (en) 2009-04-16
ZA201000255B (en) 2011-03-30
PE20090897A1 (es) 2009-08-06
ECSP109932A (es) 2010-03-31

Similar Documents

Publication Publication Date Title
EA201000050A1 (ru) Замещенные бициклолактамные соединения
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
EA201070786A1 (ru) Бензофуропиримидиноны
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
IL191629A0 (en) Tricyclic amide derivatives useful for treating obesity
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
EA201170617A1 (ru) Пиразолиламинопиридины в качестве ингибиторов fak
MA32505B1 (fr) 5-alcynyl-pyrimidines
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
DK1696905T3 (da) Substituerede 2-aminotetraliner til forebyggende behandling af Morbus Parkinson
EA201190293A1 (ru) Пролекарства триптолида
EA201000439A1 (ru) Бензотиазолы в качестве модуляторов рецептора грелина
MY139704A (en) Naphthalene derivatives for use as histamine-3-receptor ligands
EA200601295A1 (ru) Производные 1,3-диоксана и их аналоги, применимые для лечения i.a. ожирения и диабета
EA201200868A1 (ru) Ингибиторы диацилглицеролацилтрансферазы
TW200800993A (en) Organic compounds
ATE429910T1 (de) Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen